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ABSTRACT
Objective: This study aimed to evaluate the cost-effectiveness of ceftriaxone and non-ceftriaxone therapies in patients with typhoid fever.
Methods: The applied method was a cost-effectiveness analysis. Data were retrospectively collected, and sampling was performed using total 
sampling based on medical records and hospital information systems. Subjects were limited to patients diagnosed with typhoid fever and using 
ceftriaxone or non-ceftriaxone antibiotics. A total of 15 patients were investigated, comprising 10 patients on ceftriaxone and five patients using non-
ceftriaxone antibiotics. Effectiveness was evaluated by the length of hospitalization. The cost was a median of total costs, consisting of the cost of the 
drug, concomitant drugs, medical equipment, laboratory tests, doctor, health-care services, and hospitalization.
Results: The results showed the effectiveness of ceftriaxone (3.80±0.789 days) did not differ with the non-ceftriaxone drugs (3.40±1.635 days). 
However, the total cost of ceftriaxone (Rp 1,929,355) was less than that of non-ceftriaxone antibiotics (Rp 2,787,003). The average cost-effectiveness 
ratio of ceftriaxone group (Rp 507,725/effectiveness) was lower compared to the non-ceftriaxone (Rp 819,707/effectiveness).
Conclusions: This study results showed that ceftriaxone was more cost-effective than non-ceftriaxone antibiotics.
Keywords: Cost-effectiveness analysis, Typhoid fever, Hospitalization days, Ceftriaxone, Non-ceftriaxone.
INTRODUCTION
Typhoid fever is a bacterial infection caused by Salmonella enterica 
subspecies enterica serotype typhi or paratyphi A, B, or C [1]. Based 
on the WHO data, there are at least 21 million cases of typhoid fever 
and 222,000 deaths every year worldwide caused by the disease [2]. 
According to the data of Riskesdas (Indonesian Basic Health Research) 
in 2007, the prevalence of typhoid fever in Indonesia is 1.6% [3]. The 
rate of typhoid fever is estimated at 180.3/100,000 people per year [4].
In accordance with the Systematic Guideline for Typhoid Fever 
Control published in 2013, the first-line antimicrobial agents are 
chloramphenicol, ampicillin, amoxicillin (amoxicillin is safe to be used 
in pregnant patients), and trimethoprim-sulfamethoxazole. Other 
antibiotic options are also used in the treatment of typhoid fever to this 
day [5].
Ceftriaxone is an antibiotic often used for the treatment of typhoid 
fever [5]. Ceftriaxone may be used in cases of multidrug resistance 
(resistance to chloramphenicol, ampicillin, and cotrimoxazole) [6]. 
Ceftriaxone is well tolerated and can be used safely in children and 
adults [7]. Third-generation cephalosporins such as ceftriaxone or 
cefoperazone are generally well tolerated, although patients may show 
hypersensitivity reactions and can actively attack Salmonella bacteria [8].
In addition to third-generation cephalosporins, other classes of 
antibiotics such as quinolones and ciprofloxacin are also very effective 
against typhoid fever and other septic infections caused by Salmonella 
that passes through the bloodstream [9]. However, ciprofloxacin may 
have side effects on the liver and gastrointestinal tract that prolong 
hospitalization and may contribute to the development of antibiotic 
resistance, increasing the failure rate of fluoroquinolone therapy [10].
Based on the E-catalog website, ceftriaxone is relatively cheaper than 
non-ceftriaxone antibiotics [11]. This suggests that, in addition to the 
favorable efficacy of ceftriaxone over non-ceftriaxone antibiotics in the 
treatment of typhoid fever, the cost of ceftriaxone and non-ceftriaxone 
antibiotics varies enough.
Four analytical methods are used generally in pharmacoeconomic 
studies: Cost-minimalization analysis, cost-effectiveness analysis (CEA), 
cost-utility analysis, and cost-benefit analysis. These four analytical 
methods do not only consider the effectiveness, safety, and quality of 
the drugs compared but also the relevant economic aspects as well [12]. 
There are effectiveness and cost differences between ceftriaxone and 
non-ceftriaxone antibiotics; therefore, it is necessary to know which 
antibiotics will be more beneficial for hospitals and governments. CEA 
was selected for this study because it seemed to be the most appropriate 
and because it evaluates several drug treatments for the same condition 
[13]. CEA of antibiotics for typhoid fever patients has not been carried 
out before at the Cengkareng Regional General Hospital. Cengkareng 
Regional General Hospital was chosen as the site of this study because 
the hospital will prepare for the guidelines of antibiotic therapies. 
Therefore, this research can be used as a reference by policymakers in 
the hospital to determine antibiotics selection.
The effectiveness and total cost of treatment with ceftriaxone and 
non-ceftriaxone are not yet known, and which of the two treatments 
is more cost-effective in patients with typhoid fever need to be 
investigated as well. In general, this research aimed to assess the cost-
effectiveness of ceftriaxone and non-ceftriaxone antibiotics in the 
treatment of typhoid fever. In details, the purpose are (a) to assess the 
characteristics of patients participating in the study, (b) to analyze the 
effectiveness of ceftriaxone and non-ceftriaxone antibiotics in typhoid 
fever patients at Cengkareng Regional General Hospital in 2016, (c) to 
analyze the difference in total medical costs between groups of typhoid 
fever patients using ceftriaxone and non-ceftriaxone antibiotics at 
Cengkareng Regional General Hospital in 2016, and (d) to determine 
which antibiotic therapy is more cost-effective in the treatment of 
typhoid fever.
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MATERIALS AND METHODS
This study was an observational research with cross-sectional design 
and retrospective data retrieval on secondary data of patients. 
Secondary data were obtained from the patients’ medical records and 
the information systems of Cengkareng Regional General Hospital in 
2016. The results were presented descriptively and analytically. The 
research was conducted at Cengkareng Regional General Hospital, 
West Jakarta, the Special Capital Region of Jakarta from March to June 
2017. The population of this study consisted of all patients suffering 
from typhoid fever and being treated with antibiotics at Cengkareng 
Regional General Hospital in 2016. The research sample consisted of 
all hospitalized patients with typhoid fever using ceftriaxone or non-
ceftriaxone antibiotics in 2016 and met the inclusion criteria of the 
research. Sampling was done by total sampling. The inclusion criteria of 
the study were as follows: Being diagnosed with typhoid fever and using 
ceftriaxone or non-ceftriaxone antibiotics (non-ceftriaxone antibiotics 
including cefoperazone and ciprofloxacin), at least 18 years of age, 
being otherwise cured of typhoid fever by a physician, using a payment 
system with BPJS (Social Insurance Administration Organization) and 
being guaranteed to receive care class Grade 3. Exclusion criteria were 
typhoid fever with comorbid illnesses such as typhoid encephalopathy, 
septic shock, peritonitis, typhoid hepatitis, typhoid pancreatitis, 
pneumonia, and dengue fever and incomplete, lost, and not legible 
medical records.
Data analysis was performed using the IBM Statistical Package for the 
Social Science software 20.0 with 95% confidence level and α=0.05. 
The data analyses included the CEA, univariate analysis to explain or 
describe the characteristics of each research variable, sample normality 
and homogeneity analysis, and bivariate analysis. CEA was conducted 
based on the calculation of the cost-effectiveness ratio (CER), the 
incremental cost-effectiveness ratio, and sensitivity analysis aimed to 




The study was conducted retrospectively for approximately 4 months 
(March 2017 to June 2017) based on the medical and administrative 
records of the Pharmacy Installation of Cengkareng Regional General 
Hospital. There were 119 patients suffering from typhoid fever 
throughout 2016. However, only 15 patients met the inclusion criteria. 
104 patients were excluded: They had acute infectious diseases such as 
dengue fever, or their final medical diagnosis was not typhoid fever, or 
they were not treated in Grade 3. Ten patients were taking ceftriaxone 
antibiotics, and five patients were taking non-ceftriaxone antibiotics. 
Patients using non-ceftriaxone antibiotics included one patient using 
ciprofloxacin and four patients using cefoperazone. The patient group 
met the inclusion criteria of being diagnosed with typhoid fever and 
using ceftriaxone or non-ceftriaxone antibiotics. Therefore, only Ten 
patients in the ceftriaxone group and five patients in the non-ceftriaxone 
group were further analyzed.
Patient characteristics
More female than male patients participated in this research: eight 
women (53.3%) and seven men (46.7%). Five female (50.0%) and 
five male (50.0%) patients received ceftriaxone antibiotics, while 
two male (40.0%) and three female (60.0%) patients received non-
ceftriaxone antibiotics (60.0%). Based on statistical analysis, there was 
no significant difference in sex between the two groups (Table 1).
The age of patients included in the study was mostly in the adult age 
category. The age range of patients in the ceftriaxone group was in the 
range of 20–55 years, whereas the patients of the non-ceftriaxone group 
were in the age range of 25–56 years. Based on the statistical analysis, 
the statistical significance was 0.371. Therefore, it can be stated that 
there was no age difference between the two groups.
After the evaluation of patient residence data, it was found that 
14 patients were from DKI Jakarta province and only one patient came 
from outside Jakarta Province (Banten Province).
Based on patient financing sources, Cengkareng Regional General 
Hospital serves patients with insurance (BPJS) and personal source 
(cash). However, because one of the inclusion criteria was using a 
payment system with BPJS, the pharmacoeconomic analysis used the 
perspective of the payer, that is, the hospital or the government as a 
health service provider. Hospital costs in both the ceftriaxone and 
the non-ceftriaxone groups were covered by the BPJS system. BPJS 
membership was divided into two groups: Contribution beneficiaries 
(PBI) and non-contribution beneficiaries (non-PBI) (BPJS of Health, 
2013). According to Presidential Regulation No.12 of 2013 on Health 
Insurance, contribution beneficiaries of health insurance, hereinafter 
referred to as PBI health insurance, are the poor and disadvantaged 
participants of the Health Insurance Program. Nine patients were using 
the non-PBI system, while six patients were members of the PBI system.
The length of hospitalization was average for all patients. The average 
length of stay was 3.80 days in the ceftriaxone group and 3.40 days in 
the non-ceftriaxone group. Based on the statistical test, there was no 
difference in the average length of stay between the two patient groups.
CEA
Cost
A cost analysis was performed to determine the magnitude of the 
cost components involved in the treatment of ceftriaxone and non-
ceftriaxone groups by investigating the median of direct medical costs 
incurred by patients due to the use of ceftriaxone or non-ceftriaxone 
antibiotics, consisting of the cost of antibiotics, concomitant drugs, 
treatment, hospitalization, laboratory tests, and medical equipment. 
Information about the costs was obtained from SIM Cengkareng 
Regional General Hospital.
The cost of the treatment drug was the cost of intravenous or drip 
antibiotics. This cost was Rp 73,573.5 in the ceftriaxone group and 
Rp 397,024 in the non-ceftriaxone group. The difference is because 
that the non-ceftriaxone group was treated with more than one drug 
(cefoperazone and ciprofloxacin). Ceftriaxone is a first-line alternative 
as antimicrobials due to its extreme long half-life (8 h), and the use of 
them requires no costs expansion and no clinical experiments [14,15]. 
Therefore, the cost of non-ceftriaxone antibiotics was greater than the 
cost of ceftriaxone. In addition, the price of each drug was different, 
because the drugs used came from different factories. Based on the 
results of the non-parametric Mann–Whitney U-test, the statistical 
significance obtained was 0.001. Therefore, it can be stated that there 
was a difference in antibiotic costs between the ceftriaxone group and 
the non-ceftriaxone group (p<0.05) (Fig. 1).
Other drug costs incurred by patients included the cost of antiemetic 
drugs for the reduction of nausea or vomiting, supplements or vitamins 
to boost immunity, parenteral infusion, and nutrition supplies. The cost 
of concomitant drugs was Rp 662,025.5 in the ceftriaxone group and 
Rp 804,009 in the non-ceftriaxone group. Based on the non-parametric 
Mann–Whitney U-test, the significant difference was 0.679 (p>0.05). 
Therefore, it can be stated that there was no difference in the cost of 
concomitant drugs between the two groups.
The cost of medical equipment related to the use of intravenous 
antibiotics was calculated and compared between the ceftriaxone and 
non-ceftriaxone groups. The cost of medical equipment included the 
purchase of medical equipment to be used during hospitalization, such 
as 10 cc syringes, 3 cc syringes, 5 cc syringes, 1 cc syringes, needles, 
gloves, and others. The cost of medical equipment was Rp 81,256 in the 
ceftriaxone group and Rp 95,970 in the non-ceftriaxone group. Based 
on the non-parametric Mann–Whitney U-test, the significant difference 
was 0.679 (p>0.05). Therefore, it can be stated that there was no 
difference in the cost of medical equipment between the two groups.
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Laboratory test costs were costs incurred by patients due to laboratory 
examinations for diagnostic purposes, monitoring of side effects and 
therapeutic progress, or determining the outcome of therapy. Laboratory 
tests included hematological examination such as Hema I (Hb, 
hematocrit, leukocyte, and platelets), complete blood count (LED, Hb, 
Ht, erythrocytes, leukocytes, platelets, mean corpuscular volume, mean 
corpuscular hemoglobin [MCH], MCHC concentration, and count type), 
immunoserology examination using the Widal test, blood chemistry 
examination (aminotransferase, alanine aminotransferase, gamma-
glutamyl transferase, albumin, urea, creatinine, and uric acid), electrolyte 
examination, blood glucose examination, and radiological examination of 
the chest (PA/AP/RLD views). Microbiological examinations involving 
blood, urine, and feces culture tests, as well as a resistance test, were also 
performed. The cost of laboratory tests was Rp 412,500 in the ceftriaxone 
group and Rp 795,000 in the non-ceftriaxone group. Based on the non-
parametric Mann–Whitney U-test, the significant difference was 0.513 
(p>0.05). Therefore, it can be stated that there was no difference in the 
cost of laboratory tests between the two groups.
The cost of doctor visits was the cost of doctor visits during the time 
of hospitalization. The cost of doctor visits was Rp 120,000 in the 
ceftriaxone group and Rp 90,000 in the non-ceftriaxone group. Based 
on the non-parametric Mann–Whitney U-test, the significant difference 
was 0.513 (p>0.05). Therefore, it can be stated that there was no 
difference in the cost of doctor visits between the two groups.
The cost of treatment was the cost incurred by patients due to medical 
treatment during the hospitalization. The treatment included partial care, 
infusion installation, catheter installation, electrocardiogram monitor 
installation, and injection in the ER. The cost of treatment was Rp 330,000 
in the ceftriaxone group and Rp 355,000 in the non-ceftriaxone group. 
Based on the non-parametric Mann–Whitney U-test, the significant 
difference was 0.513 (p>0.05). Therefore, it can be stated that there was 
no difference in the cost of treatment between the two groups.
The cost of the room was the cost incurred by patients for hospital 
accommodation during the hospitalization. The cost of the room was Rp 
250,000 in both the ceftriaxone group and the non-ceftriaxone group. 
Based on the non-parametric Mann–Whitney U-test, the significant 
difference was 0.679 (p>0.05). Therefore, it can be stated that there was 
no difference in the cost of room between the two groups.
The total cost of treatment was calculated from the sum of all direct 
medical cost components, including the cost of antibiotics, concomitant 
drugs, medical equipment, laboratory tests, treatment, hospitalization, 
and doctors’ services for each patient. Next, the total cost of treatment 
was obtained for each group. The total cost of treatment was Rp 
1,929,355 in the ceftriaxone group and Rp 2,787,003 in the non-
ceftriaxone group. It suggested that the total cost of treatment in the 
non-ceftriaxone group was higher than in the ceftriaxone group. Based 
on the non-parametric Mann–Whitney U-test, the significant difference 
was 0.099 (p>0.05). Therefore, it can be stated that there was no 
difference in the total cost of treatment between the ceftriaxone and 
non-ceftriaxone groups.
Effectiveness
The effectiveness of the treatment was measured as the length of 
hospitalization. Data on effectiveness were obtained from the patients’ 
Table 1: Characteristics of patients using ceftriaxone and non‑ceftriaxone antibiotics at Cengkareng Regional General Hospital in 2016
Characteristics/variables Ceftriaxone n=10 (%) Non‑ceftriaxone n=5 (%) p
Gender 1.000a
Male 5 (50.0) 2 (40.0)
Female 5 (50.0) 3 (60.0)
Age (years old) 39±12.61 (20–55) 42±14.95 (25–56) 0.371b
BPJS 1.000a
Non-PBI 6 (60.0) 3 (60.0)
PBI 4 (40.0) 2 (40.0)
Origin 0.333a
DKI Jakarta 10 (100.0) 4 (80.0)
Outside Jakarta 0 (0.0) 1 (20.0)
Data are expressed in n (%) or mean±SD, Description - P: Significance of difference test, SD: Standard deviation, aChi-square test; bMann–Whitney U-test
Fig. 1: Comparison of direct medical costs between typhoid fever patients using ceftriaxone and non‑ceftriaxone antibiotics at Cengkareng 
Regional General Hospital in 2016
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medical records and the information from systems of Cengkareng 
Regional General Hospital (Table 2).
The percentage effectiveness of ceftriaxone did not differ with the non-
ceftriaxone in this study; even previous studies showed that ceftriaxone 
was more effective for typhoid fever treatment and safe to use for 
children and adults [7,16]. Ceftriaxone was also preferred because 
it was highly efficient as a typhoid fever treatment and had few side 
effects [17,18].
CER
The calculation of the CER was carried out by comparing the total 
cost of effective treatment in each treatment group [19]. The total 
cost included in the calculation was the total cost of treatment in each 
treatment group. The effectiveness included was the average length of 
hospitalization.
CER of each antibiotic group showed that the CER of the non-ceftriaxone 
group was greater (Rp 819,707/effectiveness) compared to the 
ceftriaxone group (Rp 507,725/effectiveness) (Table 3). The cost-
effective selection of drugs allowed the health-care funds to be used more 
rationally; therefore, the quality and scope of services could be improved 
[12]. Based on CER calculations, it was found that the effectiveness 
of ceftriaxone was higher with a lower total cost compared to non-
ceftriaxone antibiotics. Both groups of antibiotics met the requirements 
of a cost-effective program. However, the program chosen and the most 
cost-effective program was not always the lower cost alternative [16].
Sensitivity analysis
Sensitivity analysis was the process of testing the robustness of 
the economic evaluation by making changes to the results of the 
research [12,16]. The sensitivity analysis conducted in this research 
was a one-way sensitivity analysis, that is, a simulation of cost value 
changes with fixed effectivity value. The sensitivity analysis was carried 
out by simulating an increase in total medical expenses by increasing 
the values by 5%, 10%, and 15% (Table 4).
Based on the calculation results of the above sensitivity analysis, the 
total value of direct cost and the constant CER of ceftriaxone were lower 
than the same values calculated for the non-ceftriaxone antibiotics, 
although the total value of medical cost directly increased. Therefore, 
it can be concluded that the treatment carried out with ceftriaxone was 
more dominant than the treatment with non-ceftriaxone antibiotics.
CONCLUSIONS
Based on the results of this study, it can be concluded that the average 
CER of the ceftriaxone group (Rp 507,725/effectiveness) was lower 
compared to the non-ceftriaxone (Rp 819,707/effectiveness). This 
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